在Secukinumab启动后新发性结肠炎:一个病例报告
Hamila Hagh-Doust1, Huzaifa Nadeem2, Talat Bessissow2
1Department of Medicine, McGill University, Montreal, QC, Canada.
Case reports in gastroenterology
|December 1, 2025
概括
塞库金纽马布是一种抗素-17疗法,可能会在易感个体中引发新发炎性肠病 (IBD). 在处方抗IL-17药物之前,医生应评估IBD和多发性硬化症 (MS) 风险因素.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 类风湿病学 类风湿病学
背景情况:
- 塞库金马布向的是IL-17,一种涉及自身免疫性疾病的细胞因子.
- 在炎症性肠病 (IBD) 中观察到高IL-17A水平,但IL-17抑制可能会使IBD活动恶化.
- 多发性硬化症 (MS) 疑似与IBD相关.
研究的目的:
- 介绍一个案例,强调IL-17抑制与新发IBD之间的潜在联系.
- 为了强调在患有多种自身免疫风险因素的患者中选择生物治疗的临床考虑因素.
- 强调在开始抗IL-17治疗之前对患者病史评估的重要性.
主要方法:
- 一名22岁男性的病例报告,他有MS家族病史,因疑似结性脊髓炎而接受了secukinumab治疗.
- 在开始使用secukinumab后监测新的胃肠道症状.
- 新发性性结肠炎的诊断和治疗.
主要成果:
- 患者在开始使用secukinumab的三个月后出现性结肠炎.
- 症状通过皮质类固醇治疗得到缓解,并停止使用sequukinumab.
- 患者在治疗后5个月实现了临床和内镜缓解.
结论:
- 这一案例表明IL-17抑制与新发IBD之间存在潜在的关联.
- 在处方抗IL-17药物之前,医生必须评估IBD和其他自身免疫疾病 (如MS) 的个人和家庭病史.
- 在接受IL-17抑制剂的患者中,密切监测胃肠道症状至关重要.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
862
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
862
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
01:30Inflammatory Bowel Disease II: Crohn's Disease
925
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
925
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
01:29Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450